Posted On: 03/04/2013 3:11:12 PM
Post# of 147
AMAG Pharmaceuticals Lands in Court over Breach of Fiduciary Duties
News surfaced on February 11, 2013 that AMAG Pharmaceuticals (NASDAQ: AMAG) could be in trouble, following an announcement by Branham Law, LLP that it is investigating AMAG and certain of its officers and directors for potential breaches of fiduciary duties. This is in connection with AMAG’s apparent failure to disclose that users of the Company’s primary drug, Feraheme, have suffered adverse reactions, including hospitalizations and one possible death. This development is the outcome of the US First Circuit Court of Appeals reversing the district court’s dismissal of the claims above, which means the suit has been reinstated. We’ll briefly examine how this suit could affect AMAG’s stock..........
(0)
(0)
